4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025

4D Molecular Therapeutics, Inc.

2024-Q3 EPS reported -$2.08 revenue$36,000

Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.
Cash & equivalents $551M; expected to fund operations at least into H1 2027.
Positive 4D-150 interim data: 83% injection reduction in severe population; 70-87% 52-week injection-free rate.
4FRONT-1 Phase 3 trial for 4D-150 in wet AMD initiation expected Q1 2025.
New senior hires: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophthalmology).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.